Loading clinical trials...
Loading clinical trials...
DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study
Conditions
Interventions
treprostinil diethanolamine
placebo
Locations
30
United States
University of Alabama - Arthritis Clinical Intervention Program
Birmingham, Alabama, United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
UCLA
Los Angeles, California, United States
Stanford University School of Medicine/Palo Alto VA Health Care System
Palo Alto, California, United States
Denver Medical Center
Aurora, Colorado, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Start Date
May 1, 2009
Primary Completion Date
March 1, 2011
Completion Date
July 1, 2011
Last Updated
December 28, 2023
NCT07470151
NCT06947460
NCT07413341
NCT06801119
NCT04402086
NCT07295847
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions